{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:50:58Z","timestamp":1791618658964,"version":"4.3.4"},"reference-count":148,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.semarthrit.2008.10.002","type":"journal-article","created":{"date-parts":[[2009,1,2]],"date-time":"2009-01-02T14:22:57Z","timestamp":1230906177000},"page":"327-346","source":"Crossref","is-referenced-by-count":236,"title":["The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis"],"prefix":"10.1016","volume":"39","author":[{"given":"Daniel E.","family":"Furst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2008.10.002_bib1","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/art.11301","article-title":"Infections and anti-tumor necrosis factor alpha therapy","volume":"48","author":"Ellerin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/art.11151","article-title":"Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression","volume":"48","author":"Netea","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cyto.2004.12.012","article-title":"Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy","volume":"30","author":"Popa","year":"2005","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1086\/505430","article-title":"Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity","volume":"194","author":"Saliu","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib5","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.berh.2006.06.004","article-title":"Is IL-1 a good therapeutic target in the treatment of arthritis?","volume":"20","author":"Burger","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib6","series-title":"Immunobiology. The immune system in health and disease","author":"Janeway","year":"1999"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1521-6942(03)00041-X","article-title":"Co-morbidity in rheumatoid arthritis","volume":"17","author":"Mikuls","year":"2003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib8","first-page":"1900","article-title":"Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study","volume":"25","author":"Hernandez-Cruz","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/ard.53.4.224","article-title":"Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate","volume":"53","author":"van der Veen","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJM195310012491402","article-title":"Length of life and cause of death in rheumatoid arthritis","volume":"249","author":"Cobb","year":"1953","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib11","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.gene.6364137","article-title":"Genetic risk factors for infection in patients with early rheumatoid arthritis","volume":"5","author":"Hughes","year":"2004","journal-title":"Genes Immun"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1517\/14656566.2.7.1137","article-title":"Etanercept in rheumatoid arthritis","volume":"2","author":"Alldred","year":"2001","journal-title":"Exp Opin Pharmacother"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2165\/00003495-200059060-00010","article-title":"Infliximab: a review of its use in the management of rheumatoid arthritis","volume":"59","author":"Markham","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib16","series-title":"REMICADE\u00ae (infliximab). Prescribing information","year":"2007"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib17","first-page":"351","article-title":"Adalimumab\u2014a new TNF-\u03b1 antibody for treatment of inflammatory joint disease","volume":"3","author":"Machold","year":"2003","journal-title":"Exp Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA\u00ae) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib19","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib21","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/ard.2005.043299","article-title":"Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study","volume":"65","author":"van Riel","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib22","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib24","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib26","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-\u03b1 monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib27","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed","volume":"63","author":"van de Putte","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib28","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib30","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/ard.2005.044404","article-title":"Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study","volume":"65","author":"Weinblatt","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib31","first-page":"101","article-title":"Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland","volume":"71","author":"Cairns","year":"2002","journal-title":"Ulster Med J"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jbspin.2004.09.003","article-title":"Severe pyogenic infections in patients taking infliximab: a regional cohort study","volume":"72","author":"Maillard","year":"2005","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/art.20228","article-title":"The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis","volume":"51","author":"Hansen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib34","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1186\/ar2001","article-title":"Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity","volume":"8","author":"Vander Cruyssen","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib35","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-\u03b1 therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2515\/therapie:2003074","article-title":"[Retrospective analysis of adverse effects of infliximab in a hospital rheumatology service]","volume":"58","author":"Cabou","year":"2003","journal-title":"Therapie"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib37","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib38","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib39","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF- antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib40","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib41","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib42","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1086\/508538","article-title":"Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-\u03b1 antagonists","volume":"43","author":"Tubach","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib43","first-page":"2125","article-title":"Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment","volume":"32","author":"Bassetti","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/00365540310017474","article-title":"Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept","volume":"36","author":"Yim","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib45","first-page":"12","article-title":"Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept","volume":"65","author":"Thomas","year":"2006","journal-title":"Hawaii Med J"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib46","first-page":"526","article-title":"Mycobacteria tuberculosis peritonitis associated with etanercept therapy","volume":"21","author":"Manadan","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2005.06.006","article-title":"Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use","volume":"53","author":"Mufti","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2169\/internalmedicine.45.1623","article-title":"Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis","volume":"45","author":"Imaizumi","year":"2006","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib49","first-page":"723","article-title":"Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis","volume":"24","author":"Boulman","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib50","first-page":"112","article-title":"Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFalpha (adalimumab) treatment","volume":"63","author":"Efde","year":"2005","journal-title":"Neth J Med"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib51","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s10067-005-0164-3","article-title":"Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab","volume":"26","author":"Gutierrez-Macias","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib52","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/ard.2003.015966","article-title":"Does etanercept monotherapy enhance the risk of Listeria monocytogenes meningitis?","volume":"63","author":"Pagliano","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib53","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1128\/JCM.43.5.2537-2541.2005","article-title":"Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature","volume":"43","author":"Schett","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib54","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/art.20876","article-title":"Septic arthritis due to Listeria monocytogenes in a patient receiving etanercept","volume":"52","author":"Rachapalli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1345\/aph.1D151","article-title":"Listeria meningitis associated with infliximab","volume":"38","author":"Bowie","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib56","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/art.10374","article-title":"Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases","volume":"46","author":"Gl\u00fcck","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib57","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1345\/aph.1H407","article-title":"Parapharyngeal abscess in a patient receiving etanercept","volume":"41","author":"Borras-Blasco","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib58","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/ard.61.7.653","article-title":"Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis","volume":"61","author":"Harney","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib59","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.inf.0000055092.90609.e5","article-title":"Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept","volume":"22","author":"Elwood","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib60","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/00365540410019598","article-title":"A case of legionellosis during treatment with a TNFalpha antagonist","volume":"36","author":"Wondergem","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib61","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-136-2-200201150-00020","article-title":"Viral pneumonia as a serious complication of etanercept therapy","volume":"136","author":"Smith","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib62","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1016\/j.jinf.2004.08.015","article-title":"Pneumococcal meningitis and etanercept\u2014chance or association?","volume":"51","author":"Killingley","year":"2005","journal-title":"J Infect"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib63","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s10067-004-0950-3","article-title":"Cellulitis caused by Capnocytophaga cynodegmi associated with etanercept treatment in a patient with rheumatoid arthritis","volume":"23","author":"Gerster","year":"2004","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib64","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/00365540410021171-1","article-title":"Septic arthritis due to Salmonella enteritidis associated with infliximab use","volume":"37","author":"Katsarolis","year":"2005","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib65","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.diagmicrobio.2006.01.028","article-title":"Septic arthritis due to Roseomonas mucosa in a rheumatoid arthritis patient receiving infliximab therapy","volume":"55","author":"Sipsas","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib66","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jinf.2004.12.016","article-title":"Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis","volume":"50","author":"Jimenez","year":"2005","journal-title":"J Infect"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib67","first-page":"2432","article-title":"Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab","volume":"32","author":"Fabre","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib68","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1086\/502250","article-title":"Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?","volume":"24","author":"De Rosa","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib69","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/rheumatology\/41.3.355","article-title":"Haemorrhagic colitis due to Escherichia coli O103:H2 associated with infliximab therapy in a patient with rheumatoid arthritis","volume":"41","author":"Kirchgatterer","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib70","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/112067210601600225","article-title":"Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy","volume":"16","author":"Montero","year":"2006","journal-title":"Eur J Opthalmol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib71","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib72","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14712598.4.8.1333","article-title":"Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis","volume":"4","author":"Fleischmann","year":"2004","journal-title":"Exp Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib73","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2008.10.002_bib74","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1186\/ar1688","article-title":"The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis","volume":"7","author":"Ruderman","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib75","series-title":"ORENCIA\u00ae (abatacept)","year":"2007"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib76","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib77","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib78","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib79","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/art.22750","article-title":"Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice","volume":"56","author":"Bigbee","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib80","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib81","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib82","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"Suppl II","key":"10.1016\/j.semarthrit.2008.10.002_bib83","first-page":"436","article-title":"Rituximab abatacept and anakinra do not increase the risk of serious infections: a meta-analysis of published randomised clinical trials","volume":"66","author":"Salliot","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"suppl II","key":"10.1016\/j.semarthrit.2008.10.002_bib84","first-page":"438","article-title":"Serious infections in the rheumatoid arthritis abatacept clinical development program: an updated epidemiological assessment","volume":"66","author":"Simon","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib85","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1517\/14656566.7.18.2559","article-title":"Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis","volume":"7","author":"Dass","year":"2006","journal-title":"Exp Opin Pharmacother"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib86","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib87","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib88","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled. Phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib89","unstructured":"Emery P, Sheeran T, Lehane PB, Sa\u00ededabadi N, Shaw TM. Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis. 68th Annual Scientific Meeting, San Antonio, Texas, USA, October 16-21, 2004 [Abstract No. 1762]."},{"issue":"Suppl II","key":"10.1016\/j.semarthrit.2008.10.002_bib90","first-page":"58","article-title":"Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs","volume":"65","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib91","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl II","key":"10.1016\/j.semarthrit.2008.10.002_bib92","first-page":"88","article-title":"Long-term safety data from extended follow-up and repeat use of rituximab in rheumatoid arthritis","volume":"66","author":"van Vollenhoven","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 9","key":"10.1016\/j.semarthrit.2008.10.002_bib93","first-page":"S150","article-title":"Safety of TNF inhibitors and non-biologic dmards in rheumatoid arthritis patients previously treated with rituximab","volume":"56","author":"Genovese","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib94","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera(R))","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 3","key":"10.1016\/j.semarthrit.2008.10.002_bib95","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1186\/ar1739","article-title":"B cell non-Hodgkin's lymphoma: rituximab safety experience","volume":"7","author":"Mohrbacher","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib96","first-page":"245","article-title":"Trends in tuberculosis incidence\u2014United States, 2006","volume":"56","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib97","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib98","first-page":"217","article-title":"Trends in tuberculosis morbidity\u2014United States, 1992-2002","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib99","unstructured":"Zhao S, Makuch RW, Wentworth C, Bell D, Shibata A, Wallis WJ. Incidence rates of tuberculosis in patients with rheumatoid arthritis or ankylosing spondylitis in comparison with the general population. European League Against Rheumatism 2004, Berlin, Germany, June 9-12 2004 [Abstract No. OP0040]."},{"key":"10.1016\/j.semarthrit.2008.10.002_bib100","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib101","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib102","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib103","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"Gomez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib104","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"10.1016\/j.semarthrit.2008.10.002_bib105","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1086\/429996","article-title":"Reactivation of latent granulomatous infections by infliximab","volume":"41","author":"Wallis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib106","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib107","first-page":"S426","article-title":"Definitive results of the National French Prospective RATIO 3-year observatory on TB in patients treated with TNF blockers: the risk persists but depends on the drug","volume":"56","author":"Tubach","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib109","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/art.21688","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of JC virus infection","volume":"54","author":"Roos","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10165-006-0530-2","article-title":"Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis","volume":"17","author":"Yamamoto","year":"2007","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib111","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/107110070402500510","article-title":"Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy","volume":"25","author":"Bibbo","year":"2004","journal-title":"Foot Ankle Int"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib112","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/art.21841","article-title":"Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis","volume":"55","author":"Giles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib113","first-page":"689","article-title":"Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study","volume":"34","author":"den Broeder","year":"2007","journal-title":"J Rheumatol"},{"issue":"Suppl II","key":"10.1016\/j.semarthrit.2008.10.002_bib114","first-page":"118","article-title":"Anti-TNF therapy and the risk of serious post-operative infection: results from the BSR biologics register","volume":"66","author":"Dixon","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib115","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib116","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/rheumatology\/keh464","article-title":"Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)","volume":"44","author":"Ledingham","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib117","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/323819a0","article-title":"Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons","volume":"323","author":"Wong","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib118","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kel123","article-title":"Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis","volume":"45","author":"Roux","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib119","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/art.21216","article-title":"Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab","volume":"52","author":"Anelli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib120","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib121","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection","volume":"62","author":"Peterson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib122","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","article-title":"Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection","volume":"51","author":"Parke","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib123","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib124","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10067-006-0394-z","article-title":"Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases","volume":"26","author":"Aslanidis","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib125","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2004.05.013","article-title":"Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases","volume":"51","author":"Magliocco","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib126","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10067-006-0437-5","article-title":"Inhibition of tumour necrosis factor-alpha in patients with chronic hepatitis C infection","volume":"26","author":"Zavos","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib127","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/rheumatology\/kel191","article-title":"Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus","volume":"46","author":"Marotte","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib128","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/ard.62.7.684","article-title":"Kaposi's sarcoma associated with tumour necrosis factor alpha neutralising therapy","volume":"62","author":"Cohen","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib129","first-page":"2517","article-title":"Disseminated primary varicella infection during infliximab treatment","volume":"31","author":"Vonkeman","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib130","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1365-4632.2006.02779.x","article-title":"An atypical varicella exanthem associated with the use of infliximab","volume":"45","author":"Choi","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib131","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1086\/425123","article-title":"Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis","volume":"39","author":"Haerter","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib132","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4065\/75.10.1093","article-title":"Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis","volume":"75","author":"Aboulafia","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib133","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jbspin.2006.05.012","article-title":"Use of infliximab to treat psoriatic arthritis in HIV-positive patients","volume":"74","author":"Sellam","year":"2007","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib134","first-page":"1353","article-title":"Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection","volume":"34","author":"Linardaki","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib135","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.0007-0963.2004.05885.x","article-title":"Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab","volume":"150","author":"Bartke","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib136","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/gut.2006.101386","article-title":"Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease","volume":"55","author":"Beltran","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib137","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.rhu.0000260411.75599.39","article-title":"Successful etanercept use in an HIV-positive patient with rheumatoid arthritis","volume":"13","author":"Kaur","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib138","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib139","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/rheumatology\/kel366","article-title":"Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients","volume":"46","author":"Kapetanovic","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib140","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate. TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib141","first-page":"952","article-title":"Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone","volume":"34","author":"Visvanathan","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib142","first-page":"272","article-title":"Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab","volume":"34","author":"Kaine","year":"2007","journal-title":"J Rheumatol"},{"issue":"Suppl II","key":"10.1016\/j.semarthrit.2008.10.002_bib143","first-page":"184","article-title":"Single dose of abatacept does not prevent the development of a positive immune response to tetanus and pneumococcal vaccines","volume":"65","author":"Corbo","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"Suppl II","key":"10.1016\/j.semarthrit.2008.10.002_bib144","first-page":"437","article-title":"Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial","volume":"66","author":"Schiff","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib145","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib146","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib147","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib148","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib149","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.10.002_bib150","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/ard.2003.016014","article-title":"A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate","volume":"63","author":"Cohen","year":"2004","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017208001911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017208001911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T23:20:45Z","timestamp":1558048845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017208001911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":148,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0049017208001911"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2008.10.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}